These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25079183)

  • 1. [Subcutaneous catheter used for administration of low-molecular-weight-heparin in pediatrics].
    Márquez N R; Pino A P; Zúñiga C P
    Rev Chil Pediatr; 2014 Feb; 85(1):46-51. PubMed ID: 25079183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
    Douketis JD; Kinnon K; Crowther MA
    Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in children--an alternative to subcutaneous application when needed.
    Blatný J; Fiamoli V
    Vnitr Lek; 2009 Mar; 55(3):227-32. PubMed ID: 19378852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin administered by subcutaneous catheter is a safe and effective anti-coagulation regimen in selected inpatient infants and children with complex congenital heart disease.
    Pardun N; Lemmer J; Belker K; Pringsheim M; Ewert P; Wolf CM
    Cardiol Young; 2021 Sep; 31(9):1439-1444. PubMed ID: 33588972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of prevention of catheter-related bloodstream infection by continuous infusion of low-dose unfractionated heparin in patients with hematologic and oncologic disease.
    Abdelkefi A; Torjman L; Ladeb S; Othman TB; Achour W; Lakhal A; Hsairi M; Kammoun L; Hassen AB; Abdeladhim AB
    J Clin Oncol; 2005 Nov; 23(31):7864-70. PubMed ID: 16258088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A ten-year single-centre experience in children on chronic peritoneal dialysis--significance of percutaneous placement of peritoneal dialysis catheters.
    Aksu N; Yavascan O; Anil M; Kara OD; Erdogan H; Bal A
    Nephrol Dial Transplant; 2007 Jul; 22(7):2045-51. PubMed ID: 17438008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.
    Barbour LA; Oja JL; Schultz LK
    Am J Obstet Gynecol; 2004 Sep; 191(3):1024-9. PubMed ID: 15467584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial for maintaining peripheral intravenous lock in children.
    Mok E; Kwong TK; Chan MF
    Int J Nurs Pract; 2007 Feb; 13(1):33-45. PubMed ID: 17244243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.
    Rommers MK; Van der Lely N; Egberts TC; van den Bemt PM
    Crit Care; 2006; 10(3):R93. PubMed ID: 16790078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.
    Del Principe MI; Buccisano F; Maurillo L; Venditti D; Cefalo M; Sarlo C; Di Caprio L; Di Veroli A; Nasso D; Ceresoli E; Postorino M; Di Piazza F; Colandrea G; Conti F; Del Poeta G; Amadori S; Venditti A
    Thromb Res; 2013 Nov; 132(5):511-4. PubMed ID: 24090605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection.
    Abdelkefi A; Achour W; Ben Othman T; Ladeb S; Torjman L; Lakhal A; Ben Hassen A; Hsairi M; Ben Abdeladhim A
    J Support Oncol; 2007 Jun; 5(6):273-8. PubMed ID: 17624052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe Use of Low-Molecular-weight Heparin in Pediatric Acute Lymphoblastic Leukemia and Lymphoma Around Lumbar Punctures.
    Estepp JH; Smeltzer MP; Kang G; Howard SC; Reiss UM
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):596-601. PubMed ID: 28991127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route.
    Millet J; Jouault SC; Mauray S; Theveniaux J; Sternberg C; Boisson Vidal C; Fischer AM
    Thromb Haemost; 1999 Mar; 81(3):391-5. PubMed ID: 10102467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early administration of low molecular weight heparin after spontaneous intracerebral hemorrhage. A safety analysis.
    Kiphuth IC; Staykov D; Köhrmann M; Struffert T; Richter G; Bardutzky J; Kollmar R; Mäurer M; Schellinger PD; Hilz MJ; Doerfler A; Schwab S; Huttner HB
    Cerebrovasc Dis; 2009; 27(2):146-50. PubMed ID: 19039218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Low molecular weight heparin (dalteparin) in treatment of patients with thromboembolism incidents].
    Häfeli R; Kraljevic S; Wehrli C; Goede J; Conen D
    Praxis (Bern 1994); 2001 Aug; 90(33):1339-45. PubMed ID: 11534317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.